Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.
Also called NCT03385538
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 103 participants
- Sponsor
- Registry
-
NCT03385538
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT03385538. Allocation not applicable; no masking; primary purpose prevention. Start 2015-11-01 (actual); primary completion 2017-07-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients
- Acronym
- CLOGIS
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Zealand University Hospital
Record details
- Record id
cardio:ct-nct03385538- Content hash
024ac1ca031a9b7b78e061811558ed3d17a0aa0d64b6db1d8b121b85e79c36d6